Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABA NASDAQ:GRTS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$4.15+8.4%$3.08$1.11▼$4.16$462.00M3.183.13 million shs9.22 million shsGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%+1.03%-0.68%+13.51%+119.40%GRTSGritstone bio0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$4.15+8.4%$3.08$1.11▼$4.16$462.00M3.183.13 million shs9.22 million shsGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%+1.03%-0.68%+13.51%+119.40%GRTSGritstone bio0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 2.71Moderate Buy$17.00318.20% UpsideGRTSGritstone bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRTS and CABA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026CABACabaletta Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $16.003/24/2026CABACabaletta Bio Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$14.00 ➝ $13.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/AGRTSGritstone bio$496K7.05N/AN/A$0.54 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$167.86M-$2.28N/AN/AN/AN/A-121.73%-90.19%5/21/2026 (Estimated)GRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/ALatest GRTS and CABA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026CABACabaletta Bio-$0.41N/AN/AN/A$1.67 millionN/A3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/AGRTSGritstone bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A2.772.77GRTSGritstone bio1.832.542.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/AGRTSGritstone bio48.46%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio11.25%GRTSGritstone bio4.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio50111.33 million98.80 millionOptionableGRTSGritstone bio190108.57 million111.84 millionNo DataGRTS and CABA HeadlinesRecent News About These CompaniesGritstone Bio sets sale of assets through Bankruptcy CourtDecember 13, 2024 | bizjournals.comGritstone Oncology Inc (GRTSQ)November 27, 2024 | investing.comGritstone bio, Inc. (GRTSQ)November 22, 2024 | finance.yahoo.comFirm Retention Summary: Gritstone bioNovember 20, 2024 | wsj.comGritstone bio trumpets first data for 'multivariant' COVID jabNovember 3, 2024 | pharmaphorum.comPGritstone’s bankruptcy filing reveals biotech’s tough choicesOctober 14, 2024 | bizjournals.comGritstone Files for Bankruptcy in Effort to Save Clinical ResearchOctober 11, 2024 | biospace.comBGritstone files for bankruptcy in hope of keeping cancer vaccine R&D afloatOctober 11, 2024 | fiercebiotech.comFGritstone goes under after gruesome yearOctober 11, 2024 | thepharmaletter.comTGritstone Oncology Pursues Restructuring Through Chapter 11October 11, 2024 | finance.yahoo.comWhy Gritstone Bio (GRTS) Stock Is Down 64% TodayOctober 11, 2024 | benzinga.comStock Slide and Strategic Moves: What’s Next for Gritstone Bio (GRTS)?October 10, 2024 | bovnews.comBGritstone bio Takes Action to Preserve Value and Strengthen Capital StructureOctober 10, 2024 | businesswire.comGritstone stock craters 50% in wake of Phase 2 data, corporate updateOctober 3, 2024 | seekingalpha.comJones Trading Downgrades Gritstone bio (GRTS)October 3, 2024 | msn.comGritstone further eroded by cancer vaccine latestOctober 3, 2024 | thepharmaletter.comTGritstone downgraded by Jones, B. Riley over cancer vaccine dataOctober 3, 2024 | seekingalpha.comCash-strapped Gritstone starts search for strategic alternatives as cancer vaccine data underwhelmOctober 1, 2024 | fiercebiotech.comFKey Takeaways From Gritstone Bio Analyst RatingsOctober 1, 2024 | benzinga.comPenny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'October 1, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTS and CABA Company DescriptionsCabaletta Bio NASDAQ:CABA$4.15 +0.32 (+8.36%) Closing price 04:00 PM EasternExtended Trading$4.13 -0.02 (-0.48%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Gritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
